The rs1142345 in TPMT affects the therapeutic effect of traditional hypoglycemic herbs in prediabetes

Evidence-based Complementary and Alternative Medicine

Volumn 2013, Issue , 2013, Pages

  Li, Xi ^a   Lian, Feng Mei ^b   Guo, Dong ^a   Fan, Lan ^a   Tang, Jie ^a   Peng, Jing Bo ^a   Deng, Hong Wen ^a   Liu, Zhao Qian ^a   Xiao, Xin Hua ^c   Wang, Yan Rong ^d   Qu, Ke Yi ^e   Deng, Sheng ^f   Zhong, Qi ^f   Sha, Yi Ling ^g   Zhu, Yan ^b   Bai, Yu Jing ^b   Chen, Xin Yan ^b   Zhou, Qiang ^b   Zhou, Hong Hao ^a   Tong, Xiao Lin ^b   Zhang, Wei ^a   more..

^a CENTRAL SOUTH UNIVERSITY   (China)

^b INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^c PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^d PEKING UNIVERSITY THIRD HOSPITAL   (China)

^e Yiling Hospital   (China)

^f CENTRAL SOUTH UNIVERSITY   (China)

^g Department of Endocrinology   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DNA; HERBACEOUS AGENT; THIOPURINE METHYLTRANSFERASE; TIANQI JIANG TANG; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIDIABETIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUTATIONAL ANALYSIS; PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84877989673     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2013/327629     Document Type: Article

References (42)

1. Roglic G., Unwin N., Bennett P. H., Mathers C., Tuomilehto J., Nag S., Connolly V., King H., The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care 2005 28 9 2130 2135 2-s2.0-24144472565 10.2337/diacare.28.9.2130 (Pubitemid 41242456)
2. Gupta A., Gupta R., Sarna M., Rastogi S., Gupta V. P., Kothari K., Prevalence of diabetes, impaired fasting glucose and insulin resistance syndrome in an urban Indian population. Diabetes Research and Clinical Practice 2003 61 1 69 76 2-s2.0-0038721799 10.1016/S0168-8227(03)00085-8 (Pubitemid 36808845)
3. Yang W., Lu J., Weng J., Jia W., Ji L., Xiao J., Shan Z., Liu J., Tian H., Ji Q., Zhu D., Ge J., Lin L., Chen L., Guo X., Zhao Z., Li Q., Zhou Z., Shan G., He J., Prevalence of diabetes among men and women in China. The New England Journal of Medicine 2010 362 12 1090 1101 2-s2.0-77950263954 10.1056/NEJMoa0908292
4. Union O. E., Health at a Glance: Europe 2010 OECD Publishing
5. C. f. D. C. a. Prevention, National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and preDiabetes in the United States 2011 Atlanta, Ga, USA Department of Health and Human Services, Centers for Disease Control and Prevention
6. Wild S., Roglic G., Green A., Sicree R., King H., Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004 27 5 1047 1053 2-s2.0-2342466734 10.2337/diacare.27.5.1047 (Pubitemid 38579764)
7. Abdul-Ghani M. A., Tripathy D., DeFronzo R. A., Contributions of β -cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 2006 29 5 1130 1139 2-s2.0-33746377965 10.2337/diacare.2951130 (Pubitemid 44115261)
8. Perreault L., Pan Q., Mather K. J., Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the diabetes prevention program outcomes study. The Lancet 2012 379 9833 2243 2251
9. Buchanan T. A., Xiang A. H., Peters R. K., Kjos S. L., Marroquin A., Goico J., Ochoa C., Tan S., Berkowitz K., Hodis H. N., Azen S. P., Preservation of pancreatic β -cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002 51 9 2796 2803 2-s2.0-0036724346 (Pubitemid 34970933)
10. Nebert D. W., Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? Clinical Genetics 1999 56 4 247 258 2-s2.0-0032748555 10.1034/j.1399-0004.1999.560401.x
11. Almoguera B., Riveiro-Alvarez R., Gomez-Dominguez B., Lopez-Rodriguez R., Dorado P., Vaquero-Lorenzo C., Dal-Ré R., Fernandez-Piqueras J., Llerena A., Abad-Santos F., Ayuso C., Evaluating a newly developed pharmacogenetic array: screening in a Spanish population. Pharmacogenomics 2010 11 11 1619 1625 2-s2.0-78649704941 10.2217/pgs.10.131
12. Burmester J. K., Sedova M., Shapero M. H., Mansfield E., DMET microarray technology for pharmacogenomics-based personalized medicine. Methods in Molecular Biology 2010 632 99 124 2-s2.0-77951746794 10.1007/978-1-60761-663-4-7
13. Gardiner S. J., Begg E. J., Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacological Reviews 2006 58 3 521 590 2-s2.0-33748787999 10.1124/pr.58.3.6 (Pubitemid 44403684)
14. Zhao Q. L., Guo B. R., Yang W. J., Tianqi capsule treat Type 2 diabetes: a trial of 300 cases. Journal of Shandong University of Traditional Chinese Medicine 2003 27 3 191 192
15. Cai H. Q., Ge H. Q., Zhang X. J., Bai L. W., Tianqi capsule treat Type 2 diabetes: a trial of 60 cases. Journal of Jilin University 2003 29 5 669 671
16. Zhang S. X., Sun H., Sun W. J., Jiao G. Z., Wang X. J., Proteomic study of serum proteins in a type 2 diabetes mellitus rat model by Chinese traditional medicine Tianqi Jiangtang Capsule administration. Journal of Pharmaceutical and Biomedical Analysis 2010 53 4 1011 1014 2-s2.0-77955581604 10.1016/j.jpba.2010. 06.033
17. Cai H. G. H., Zhang H., Bai L., Clinical observation on treating 60 patients with type 2 diabetes by capsule Tianqi. Journal of Jilin University 2003 29 5 669 671
18. Wu Y., Ou-Yang J. P., Wu K., Wang Y., Zhou Y. F., Wen C. Y., Hypoglycemic effect of Astragalus polysaccharide and its effect on PTP1B. Acta Pharmacologica Sinica 2005 26 3 345 352 2-s2.0-15244348325 10.1111/j.1745-7254. 2005.00062.x (Pubitemid 40388072)
19. Zou F., Mao X. Q., Wang N., Liu J., Ou-Yang J. P., Astragalus polysaccharides alleviates glucose toxicity and restores glucose homeostasis in diabetic states via activation of AMPK. Acta Pharmacologica Sinica 2009 30 12 1607 1615 2-s2.0-74949118250 10.1038/aps.2009.168
20. Tang L. Q., Wei W., Chen L. M., Liu S., Effects of berberine on diabetes induced by alloxan and a high-fat/high-cholesterol diet in rats. Journal of Ethnopharmacology 2006 108 1 109 115 2-s2.0-33749327046 10.1016/j.jep.2006.04. 019 (Pubitemid 44498992)
21. Yin J., Xing H., Ye J., Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism 2008 57 5 712 717 2-s2.0-42949145899 10.1016/j.metabol.2008.01.013 (Pubitemid 351608234)
22. Wang C., Li J., Lv X., Zhang M., Song Y., Chen L., Liu Y., Ameliorative effect of berberine on endothelial dysfunction in diabetic rats induced by high-fat diet and streptozotocin. European Journal of Pharmacology 2009 620 1-3 131 137 2-s2.0-70349157209 10.1016/j.ejphar.2009.07.027
23. Attele A. S., Zhou Y. P., Xie J. T., Wu J. A., Zhang L., Dey L., Pugh W., Rue P. A., Polonsky K. S., Yuan C. S., Antidiabetic effects of Panax ginseng berry extract and the identification of an effective component. Diabetes 2002 51 6 1851 1858 2-s2.0-0036266324 (Pubitemid 34564298)
24. Cho W. C. S., Chung W. S., Lee S. K. W., Leung A. W. N., Cheng C. H. K., Yue K. K. M., Ginsenoside Re of Panax ginseng possesses significant antioxidant and antihyperlipidemic efficacies in streptozotocin-induced diabetic rats. European Journal of Pharmacology 2006 550 1-3 173 179 2-s2.0-33749990092 10.1016/j.ejphar.2006.08.056 (Pubitemid 44572271)
25. Cho W. C. S., Yip T. T., Chung W. S., Lee S. K. W., Leung A. W. N., Cheng C. H. K., Yue K. K. M., Altered expression of serum protein in ginsenoside Re-treated diabetic rats detected by SELDI-TOF MS. Journal of Ethnopharmacology 2006 108 2 272 279 2-s2.0-33749997319 10.1016/j.jep.2006.05.009 (Pubitemid 44635032)
26. Sakai K., Matsumoto K., Nishikawa T., Suefuji M., Nakamaru K., Hirashima Y., Kawashima J., Shirotani T., Ichinose K., Brownlee M., Araki E., Mitochondrial reactive oxygen species reduce insulin secretion by pancreatic β -cells. Biochemical and Biophysical Research Communications 2003 300 1 216 222 2-s2.0-0037228626 10.1016/S0006-291X(02)02832-2 (Pubitemid 36042955)
27. Liu X., Han Z. P., Wang Y. L., Gao Y., Zhang Z. Q., Analysis of the interactions of multicomponents in Cornus officinalis Sieb. et Zucc. with human serum albumin using on-line dialysis coupled with HPLC. Journal of Chromatography B 2011 879 9-10 599 604 2-s2.0-79952194731 10.1016/j.jchromb. 2011.01.022
28. Gu Y., Zhang Y., Shi X., Li X., Hong J., Chen J., Gu W., Lu X., Xu G., Ning G., Effect of traditional Chinese medicine berberine on type 2 diabetes based on comprehensive metabonomics. Talanta 2010 81 3 766 772 2-s2.0-77949336458 10.1016/j.talanta.2010.01.015
29. Zhang H., Wei J., Xue R., Wu J. D., Zhao W., Wang Z. Z., Wang S. K., Zhou Z. X., Song D. Q., Wang Y. M., Pan H. N., Kong W. J., Jiang J. D., Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism 2010 59 2 285 292 2-s2.0-74049139484 10.1016/j.metabol.2009.07.029
30. - microparticles is associated with improvement of endothelial function in humans. European Journal of Pharmacology 2009 614 1-3 77 83 2-s2.0-67349206613 10.1016/j.ejphar.2009.04.037
31. Zhang Y., Li X., Zou D., Liu W., Yang J., Zhu N., Huo L., Wang M., Hong J., Wu P., Ren G., Ning G., Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. Journal of Clinical Endocrinology and Metabolism 2008 93 7 2559 2565 2-s2.0-47549100864 10.1210/jc.2007-2404 (Pubitemid 352008520)
32. WHO, Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycaemia 2006
33. Lennard L., Van Loon J. A., Weinshilboum R. M., Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clinical Pharmacology and Therapeutics 1989 46 2 149 154 2-s2.0-0024451147 (Pubitemid 19219950)
34. Otterness D., Szumlanski C., Lennard L., Klemetsdal B., Aarbakke J., Park-Hah J. O., Iven H., Schmiegelow K., Branum E., O'Brien J., Weinshilboum R., Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clinical Pharmacology and Therapeutics 1997 62 1 60 73 2-s2.0-12644291917 10.1016/S0009-9236(97)90152-1 (Pubitemid 27327100)
35. Franke R. M., Lancaster C. S., Peer C. J., Gibson A. A., Kosloske A. M., Orwick S. J., Mathijssen R. H., Figg W. D., Baker S. D., Sparreboom A., Effect of ABCC2 (MRP2) transport function on erythromycin metabolism. Clinical Pharmacology and Therapeutics 2011 89 5 693 701 2-s2.0-79955475552 10.1038/clpt.2011.25
36. Qu J., Zhou B. T., Yin J. Y., ABCC2 polymorphisms and haplotype are associated with drug resistance in Chinese epileptic patients. CNS Neuroscience & Therapeutics 2012 18 8 647 651 10.1111/j.1755-5949.2012.00336.x
37. Keskitalo J. E., Pasanen M. K., Neuvonen P. J., Niemi M., Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics 2009 10 10 1617 1624 2-s2.0-70649110001 10.2217/pgs.09.85
38. Shikata E., Yamamoto R., Takane H., Shigemasa C., Ikeda T., Otsubo K., Ieiri I., Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. Journal of Human Genetics 2007 52 2 117 122 2-s2.0-33846617263 10.1007/s10038-006-0087-0 (Pubitemid 46185105)
39. Imanaga J., Kotegawa T., Imai H., Tsutsumi K., Yoshizato T., Ohyama T., Shirasaka Y., Tamai I., Tateishi T., Ohashi K., The effects of the SLCO2B1 c.1457C>T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans. Pharmacogenetics and Genomics 2011 21 2 84 93 2-s2.0-78751614878 10.1097/FPC.0b013e32834300cc
40. Blum M., Demierre A., Grant D. M., Heim M., Meyer U. A., Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proceedings of the National Academy of Sciences of the United States of America 1991 88 12 5237 5241 2-s2.0-0025948280 10.1073/pnas.88.12.5237 (Pubitemid 21914719)
41. De Morais S. M. F., Wilkinson G. R., Blaisdell J., Nakamura K., Meyer U. A., Goldstein J. A., The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. The Journal of Biological Chemistry 1994 269 22 15419 15422 2-s2.0-0028260641
42. Sugatani J., Yamakawa K., Yoshinari K., Machida T., Takagi H., Mori M., Kakizaki S., Sueyoshi T., Negishi M., Miwa M., Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia. Biochemical and Biophysical Research Communications 2002 292 2 492 497 2-s2.0-18444399926 10.1006/bbrc.2002.6683 (Pubitemid 34694291)